Central Oncology Review
Advarra meets the growing needs of oncology by offering robust human subject protections that cancer research institutions expect.
IBC
IBC Registration Form
Join the Gene Therapy Network to accelerate study activation, gain IBC support, and position your site as a preferred choice for sponsors.
IBC Review and Consulting Services
Advarra’s biosafety experts streamline startup for gene therapy trials with comprehensive IBC reviews and proven rapid turnaround times.
Materials Required for Submitting a Study to the IBC
Comprehensive IBC submissions require detailed materials, including investigator CVs, safety protocols, and site-specific SOPs for study agent handling.
Bacteriophage Therapy: A Promising Solution to Antibiotic Resistance
Antibiotic resistance is an emerging problem. Some have argued bacteria are developing antibiotic resistance faster than we can research, develop,
Institutional Biosafety Committee (IBC) Services Info Sheet
Advarra’s IBC services offer rapid, flexible solutions for IBC review, especially critical for gene therapy and other high-stakes research.
Diversity, Equity, and Inclusion in Clinical Research
Achieving diversity, equity, and inclusion (DEI) in clinical trials is crucial for producing comprehensive and effective medical research benefitting all
Decentralized Clinical Trials Involving Biologics: Unique Challenges
Join this webinar to learn about FDA insights on DCTs and biologics. Dr. Eisenman discusses biosafety, risks, and key considerations for safe trials.
Preparing Your Action Plan for the FDA sIRB Mandate
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Conducting Research With CAR T Cells
Conducting Research With CAR T Cells Regulatory and Practical Considerations Having proven successful in trials for blood cancers considered resistant
The Importance of Hazard Communications in Clinical Trials Involving Genetic Engineering
Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their
CAR T Manufacturing and Toxicity
CAR T Manufacturing and Toxicity Pre-Clinical Considerations Genetically engineered therapeutics present diverse, and sometimes heightened, risks compared to traditional small